EUCTR2015-000159-26-ES进行中（未招募）1 期
A Phase 2a, Multi-centre, Single-arm Trial of the Combination of AZD2014 and Weekly Paclitaxel in Patients with Relapsed or Refractory Squamous Non-Small Cell Lung Cancer After at Least One Line of Prior Therapy - STORK
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Histologically or cytologically proven squamous non-small cell lung cancer (NSCLC) where treatment with weekly paclitaxel is an appropriate treatment option.
- •2.Relapsed or refractory disease after at least one line of prior therapy. Subjects must have previously received appropriate lines of standard of care (SOC) treatment.
- •3.Measurable disease by RECIST v1.1 criteria
- •4.Life expectancy of at least 12 weeks.
- •5.Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- •6.Adequate hematologic function independent of transfusion and growth factor support for at least 7 days prior to screening (with the exception of pegylated G-CSF (pegfilgrastim) and darbopoeitin which require at least 14 days prior to screening), defined as:
- •?Absolute neutrophil count ?? 1500 cells/mm3 (1.5 x 109/L)
- •?Platelet count ? ?100,000 cells/mm3 (100 x 109/L)
- •?Haemoglobin ? ?9.0 g/dL
- •7.Adequate hepatic and renal function defined as:
- •?Serum aspartate transaminase (AST) or alanine transaminase (ALT) ?? 2.5 x upper limit of normal (ULN) if no demonstrable liver metastases or ?? 5 x ULN in the presence of liver metastases
- •?Alkaline phosphatase (ALP) < 5 x ULN
- •?Serum bilirubin ?? 1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin)
- •?Estimated Creatinine Clearance ? ? 50 ml/min (Cockroft Gault) or serum creatinine ?? 1.5 x ULN
- •8.PT/INR <1.5 x ULN and PTT (aPTT) <1.5 x ULN
- •9.Fasting glucose ?? 125 mg/dL (7 mmol/L) and erythrocyte-HbA1c ?? 59 mmol/mol
- •10.Men and women ? ? 18 years of age
- •11.Female patients must fulfil either of the 2 following main criteria:
- •?Not of childbearing potential, defined as:
- •?Post-menopausal women: Either women aged more than 50 years and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments, or, women under 50 years old who have been amenorrhoeic for at least 12 months following the cessation of exogenous hormonal treatments, and have serum follicle-stimulating hormone (FSH) and luteininzing hormone (LH) levels in the postmenopausal range for the institution.
- •?Have documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation
- •?Have a negative pregnancy test prior to start of dosing, shoudl not be breastfeeding, and willing to use two forms of highly effective contraception (per institution standards) from the time of screening until 4 weeks after discontinuing study treatment (see Section 3.8)
- •12.Male patients must use an effective barrier method of contraception during the study and for 16 weeks following the last dose if sexually active with a female of childbearing potential
- •13.Able to swallow and retain oral medication
- •14.Written (signed and dated) informed consent (including provision of consent for collection of formalin fixed paraffin-embedded blocks or slides from archival histology or cytology samples, where available) and be capable of co-operating with treatment and follow up
- •Inclusion in biopsy research
- •For inclusion in the biopsy research of the study, patients must fulfil the following additional criterion:
- •?Provision of signed, written and dated informed consent for biomarker sampling analyses. Sampling will include the provision of tumour biopsies . If a patient declines to participate in this research, there will be no penalty or loss of benefit to the patient. The patient will not be excluded from other aspects of the stud;
- •1.Histologically or cytologically proven squamous non-small cell lung cancer (NSCLC) where treatment with weekly paclitaxel is an appropriate treatment option.
- •2.Relapsed or refractory disease after at least one line of prior therapy. Subjects must have previously received appropriate lines of standard of care (SOC) treatment.
- •3.Measurable disease by RECIST v1.1 criteria
- •4.Life expectancy of at least 12 weeks.
- •5.Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- •6.Adequate hematologic function independent of transfusion and growth factor support for at least 7 days prior to screening (with the exception of pegylated G-CSF (pegfilgrastim) and darbopoeitin which require at least 14 days prior to screening), defined as:
- •?Absolute neutrophil count ?? 1500 cells/mm3 (1.5 x 109/L)
- •?Platelet count ? ?100,000 cells/mm3 (100 x 109/L)
- •?Haemoglobin ? ?9.0 g/dL
- •7.Adequate hepatic and renal function defined as:
- •?Serum aspartate transaminase (AST) or alanine transaminase (ALT) ?? 2.5 x upper limit of normal (ULN) if no demonstrable liver metastases or ?? 5 x ULN in the presence of liver metastases
- •?Alkaline phosphatase (ALP) < 5 x ULN
- •?Serum bilirubin ?? 1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin)
- •?Estimated Creatinine Clearance ? ? 50 ml/min (Cockroft Gault) or serum creatinine ?? 1.5 x ULN
- •8.PT/INR <1.5 x ULN and PTT (aPTT) <1.5 x ULN
- •9.Fasting glucose ?? 125 mg/dL (7 mmol/L) and erythrocyte-HbA1c ?? 59 mmol/mol
- •10.Men and women ? ? 18 years of age
- •11.Female patients must fulfil either of the 2 following main criteria:
- •?Not of childbearing potential, defined as:
- •?Post-menopausal women: Either women aged more than 50 years and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments, or, women under 50 years old who have been amenorrhoeic for at least 12 months following the cessation of exogenous hormonal treatments, and have serum follicle-stimulating hormone (FSH) and luteininzing hormone (LH) levels in the postmenopausal range for the institution.
- •?Have documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation
- •?Have a negative pregnancy test prior to start of dosing, shoudl not be breastfeeding, and willing to use two forms of highly effective contraception (per institution standards) from the time of screening until 4 weeks after discontinuing study treatment (see Section 3.8)
- 另有 34 项未显示
排除标准
- •1.Radiotherapy (except for palliative reasons), chemotherapy, endocrine therapy, or immunotherapy during the previous 3 weeks (4 weeks for investigational medicinal products and 6 weeks for nitrosoureas and Mitomycin-C) before treatment .
- •2.Ongoing toxic manifestations of previous treatments. Exceptions to this are alopecia or Grade 1 toxicities, which in the opinion of the Investigator should not exclude the patient.
- •3.Known leptomeningeal involvement, brain metastases or spinal cord compression.
- •4.History of hypersensitivity (> Grade 2) to active or inactive excipients of AZD2014, drugs containing Cremophor, taxanes or structurally/chemically similar drugs
- •5.Current refractory nausea and vomiting, chronic gastrointestinal disease, inability to swallow formulated product or previous significant bowel resection that would preclude adequate absorption of AZD2014
- •6.Patients with Diabetes Type I or uncontrolled Type II (HbA1c > 59 mmol/mol assessed locally) as judged by the investigator
- •7.Major surgery within 4 weeks prior to entry to the study (excluding placement of vascular access), or minor surgery within 2 weeks of entry into the study and from which the patient has not yet recovered
- •8.Treatment with warfarin. Patients on warfarin for DVT/PE can be converted to LMWH.
- •9.Exposure to potent or moderate inhibitors or inducers of CYP3A4/5 if taken within the stated washout periods before the first dose of study treatment (see Appendix G)
- •10.Exposure to potent or moderate inhibitors or inducers of CYP2C8 if taken within the stated washout periods before the first dose of study treatment (see Appendix G)
- •11.Exposure to sensitive or narrow therapeutic range substrates of the drug metabolising enzymes CYP2C8, CYP2C9, CYP2C19, CYP2D6 or the drug transporters Pgp (MDR1), BCRP, OATP1B1, OATP1B3, OCT1 and OCT2 within the appropriate wash-out period (a minimum of 5 times reported elimination half-life) before the first dose of study treatment (see Appendix G)
- •12.At high medical risk because of non-malignant systemic disease including active uncontrolled infection e.g. interstitial lung disease, severe hepatic impairment, uncontrolled chronic renal disease
- •13.Known to be serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV)
- •14.Patients who have experienced any of the following procedures or conditions currently or in the preceding 12 months:
- •?coronary artery bypass graft
- •?angioplasty
- •?vascular stent
- •?myocardial infarction (MI)
- •?uncontrolled angina pectoris
- •?congestive heart failure NYHA Grade 2
- •?ventricular arrhythmias requiring continuous therapy
- •?supraventricular arrhythmias including AF, which are uncontrolled
- •?Torsades de Pointes
- •?haemorrhagic or thrombotic stroke, including transient ischaemic attacks or any other central nervous system bleeding
- •15.Resting ECG with measurable QTcF interval of >470 msec at 2 or more time points within a 24 hour period.
- •16.Concomitant medications known to prolong QT interval, or with factors that increase the risk of QTc prolongation or risk of arrhythmic events (such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome), or unexplained sudden death under 40 years of age. Inability to discontinue medication with agents designated as having a risk of Torsades de Pointes due to QT prolongation
- •17.Left ventricular (LV) dysfunction (LVEF outside institutional range of normal) by MUGA or Echocardiogram
- •1.Radiotherapy (except for palliative reasons), chemotherapy, endocrine therapy, or immunotherapy during the previous 3 weeks (4 weeks for investigational medicinal products and 6 weeks for nitrosoureas and Mitomycin-C) before treatment .
- •2.Ongoing toxic manifestations of previous treatments. Exceptions to this are alopecia or Grade 1 toxicities, which in the opinion of the Investigator should not exclude the patient.
- •3.Known leptomeningeal involvement, brain metastases or spinal cord compression.
- •4.History of hypersensitivity (> Grade 2) to active or inactive excipients of AZD2014, drugs containing Cremophor, taxanes or structurally/chemically similar drugs
- •5.Current refractory nausea and vomiting, chronic gastrointestinal disease, inability to swallow formulated product or previous significant bowel resection that would preclude adequate absorption of AZD2014
- •6.Patients with Diabetes Type I or uncontrolled Type II (HbA1c > 59 mmol/mol assessed locally) as judged by the investigator
- •7.Major surgery within 4 weeks prior to entry to the study (excluding placement of vascular access), or minor surgery within 2 weeks of entry into the study and from which the patient has not yet recovered
- •8.Treatment with warfarin. Patients on warfarin for DVT/PE can be converted to LMWH.
- •9.Exposure to potent or moderate inhibitors or inducers of CYP3A4/5 if taken within the stated washout periods before the first dose of study treatment (see Appendix G)
- •10.Exposure to potent or moderate inhibitors or inducers of CYP2C8 if taken within the stated washout periods before the first dose of study treatment (see Appendix G)
- •11.Exposure to sensitive or narrow therapeutic range substrates of the drug metabolising enzymes CYP2C8, CYP2C9, CYP2C19, CYP2D6 or the drug transporters Pgp (MDR1), BCRP, OATP1B1, OATP1B3, OCT1 and OCT2 within the appropriate wash-out period (a minimum of 5 times reported elimination half-life) before the first dose of study treatment (see Appendix G)
- •12.At high medical risk because of non-malignant systemic disease including active uncontrolled infection e.g. interstitial lung disease, severe hepatic impairment, uncontrolled chronic renal disease
- •13.Known to be serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV)
- •14.Patients who have experienced any of the following procedures or conditions currently or in the preceding 12 months:
- •?coronary artery bypass graft
- •?angioplasty
- •?vascular stent
- •?myocardial infarction (MI)
- •?uncontrolled angina pectoris
- •?congestive heart failure NYHA Grade 2
- •?ventricular arrhythmias requiring continuous therapy
- •?supraventricular arrhythmias including AF, which are uncontrolled
- •?Torsades de Pointes
- 另有 31 项未显示
研究者
相似试验
进行中（未招募）
不适用
/APatients with Locally Advanced or Metastatic Adenocarcinomas of the Stomach and Gastro-esophageal junctionEUCTR2012-002179-32-GRHellenic Oncology Research Group (H.O.R.G.)
进行中（未招募）
1 期
A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE® Antibody Blinatumomab in Adult Subjects with Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia (Alcantara Study) - Alcantara StudyAdult patients with relapsed and/or refractory Philadelphia Chromosome- positive B-precursor ALLMedDRA version: 16.0Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864MedDRA version: 16.0Level: LLTClassification code 10063625Term: Acute lymphoblastic leukemia recurrentSystem Organ Class: 100000004864EUCTR2013-000706-36-ITAmgen Inc.45
进行中（未招募）
1 期
Clinical Phase 2 Study to evaluate the efficacy of the bispecific antibody blinatumomab in adult subjects with Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) that did not respond to previous therapy or that relapsed after initially successful previous therapy.Adult patients with relapsed and/or refractory Philadelphia Chromosome- positive B-precursor ALLMedDRA version: 19.0Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10063625Term: Acute lymphoblastic leukemia recurrentSystem Organ Class: 100000004864EUCTR2013-000706-36-GBAmgen Inc.45
进行中（未招募）
1 期
Clinical Phase 2 Study to evaluate the efficacy of the bispecific antibody blinatumomab in adult subjects with Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) that did not respond to previous therapy or that relapsed after initially successful previous therapy.Adult patients with relapsed and/or refractory Philadelphia Chromosome- positive B-precursor ALLMedDRA version: 20.0Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000012958MedDRA version: 20.0Level: LLTClassification code 10063625Term: Acute lymphoblastic leukemia recurrentSystem Organ Class: 100000012975EUCTR2013-000706-36-DEAmgen Inc.41
进行中（未招募）
1 期
A clinical study exploring the effect of osimertinib and radiation therapy, in people with newly diagnosed non-small cell lung cancer (NSCLC) that has spread to a few other parts of the body and shows a change (mutation) in the EGFR gene.MedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Treatment naïve patients with synchronous, oligo-metastatic (primary tumour and maximum 5 metastases) EGFR-mutant (exon 19 deletion or exon 21 L858R) NSCLC with or without T790M resistance mutationMedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-004114-35-NLETOP IBCSG Partners Foundation60